| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Russ Altman | Q7381092 |
| Jennifer L Wilson | Q57030914 | ||
| P2860 | cites work | Basket Trials and the Evolution of Clinical Trial Design in an Era of Genomic Medicine | Q63199223 |
| NCI-MATCH launch highlights new trial design in precision-medicine era | Q85528297 | ||
| Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer | Q86558618 | ||
| DrugBank: a comprehensive resource for in silico drug discovery and exploration | Q24188653 | ||
| Using N-of-1 trials to improve patient management and save costs | Q24594944 | ||
| What are biomarkers? | Q24613362 | ||
| Pharmacogenomics knowledge for personalized medicine | Q24623166 | ||
| CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network | Q24632735 | ||
| A global reference for human genetic variation | Q25909434 | ||
| Revolutionizing Alzheimer's disease and clinical trials through biomarkers | Q26744882 | ||
| Precision medicine in patients with allergic diseases: Airway diseases and atopic dermatitis-PRACTALL document of the European Academy of Allergy and Clinical Immunology and the American Academy of Allergy, Asthma & Immunology | Q26751386 | ||
| Biomarker-based drug safety assessment in the age of systems pharmacology: from foundational to regulatory science | Q26778374 | ||
| Big Data: the challenge for small research groups in the era of cancer genomics | Q26780460 | ||
| Predictive biomarkers in precision medicine and drug development against lung cancer | Q26824536 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer | Q27851691 | ||
| Personalized Medicine in Allergy | Q28073074 | ||
| Precision medicine: from pharmacogenomics to pharmacoproteomics | Q28076871 | ||
| Genome-wide epigenomic profiling for biomarker discovery | Q28080102 | ||
| Biomarkers and surrogate endpoints: preferred definitions and conceptual framework | Q28203935 | ||
| Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial | Q28300531 | ||
| Biomarker-Defined Subsets of Common Diseases: Policy and Economic Implications of Orphan Drug Act Coverage | Q28468454 | ||
| Network-based in silico drug efficacy screening | Q28601372 | ||
| Digital Health: Tracking Physiomes and Activity Using Wearable Biosensors Reveals Useful Health-Related Information | Q29248634 | ||
| A new initiative on precision medicine | Q29615654 | ||
| Collaborative biomedicine in the age of big data: the case of cancer | Q30795848 | ||
| The Cancer Genomics Hub (CGHub): overcoming cancer through the power of torrential data | Q30856212 | ||
| Identification of drug-specific pathways based on gene expression data: application to drug induced lung injury | Q30941816 | ||
| From big data analysis to personalized medicine for all: challenges and opportunities | Q30976798 | ||
| New Tools for New Research in Psychiatry: A Scalable and Customizable Platform to Empower Data Driven Smartphone Research | Q31091721 | ||
| Utilizing a Personal Smartphone Custom App to Assess the Patient Health Questionnaire-9 (PHQ-9) Depressive Symptoms in Patients With Major Depressive Disorder. | Q33445808 | ||
| Mobile Mental Health: Navigating New Rules and Regulations for Digital Tools | Q33450347 | ||
| Synthetic lethality: emerging targets and opportunities in melanoma | Q33578398 | ||
| Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans | Q33591111 | ||
| Anthracycline induced cardiotoxicity: biomarkers and "Omics" technology in the era of patient specific care | Q33658456 | ||
| Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine | Q33725390 | ||
| Integrated systems pharmacology analysis of clinical drug-induced peripheral neuropathy. | Q33733061 | ||
| Most random gene expression signatures are significantly associated with breast cancer outcome | Q34058091 | ||
| Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease | Q34157492 | ||
| The interface between biomarker discovery and clinical validation: The tar pit of the protein biomarker pipeline | Q34215058 | ||
| Identification of high-quality cancer prognostic markers and metastasis network modules | Q34275507 | ||
| Biomarker tests for the diagnosis of Alzheimer's disease: Generating evidence to inform insurance coverage determinations | Q34375406 | ||
| Clinical development success rates for investigational drugs | Q34396786 | ||
| From accuracy to patient outcome and cost-effectiveness evaluations of diagnostic tests and biomarkers: an exemplary modelling study. | Q34569710 | ||
| Current and future role of biomarkers in Crohn's disease risk assessment and treatment | Q35095265 | ||
| Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial | Q35168763 | ||
| Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis | Q35587325 | ||
| Biomarkers and surrogate markers: an FDA perspective | Q36045270 | ||
| Prediction of polypharmacological profiles of drugs by the integration of chemical, side effect, and therapeutic space | Q46181348 | ||
| Personalized medicine: Time for one-person trials | Q46268988 | ||
| Clinically Useful Genetic Markers of Antidepressant Response: How Do We Get There From Here? | Q47663704 | ||
| Analyzing global trends of biomarker use in drug interventional clinical studies. | Q47723116 | ||
| When do new biomarkers make economic sense? | Q48179662 | ||
| Preemptive Panel-Based Pharmacogenetic Testing: The Time is Now. | Q50678072 | ||
| Adverse drug events: database construction and in silico prediction. | Q51241453 | ||
| Biomarker Tests for Molecularly Targeted Therapies--The Key to Unlocking Precision Medicine. | Q51275924 | ||
| Computed Biological Relations among Five Select Treatment-Related Organ/Tissue Toxicities. | Q51379426 | ||
| Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma | Q56895636 | ||
| UK Biobank: Current status and what it means for epidemiology | Q57655303 | ||
| ??? | Q28071939 | ||
| Novel insights into the genetics of smoking behaviour, lung function, and chronic obstructive pulmonary disease (UK BiLEVE): a genetic association study in UK Biobank | Q36123192 | ||
| Blood pressure as an example of a biomarker that functions as a surrogate | Q36439163 | ||
| Biomarkers and surrogate endpoints in clinical trials | Q36552129 | ||
| Changing paradigm of cancer therapy: precision medicine by next-generation sequencing | Q36849642 | ||
| Proteomics as a tool for biomarker discovery | Q37023642 | ||
| Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. | Q37107608 | ||
| Rates, variability, and associated factors of polypharmacy in nursing home patients | Q37360389 | ||
| Personal genomic measurements: the opportunity for information integration | Q37635920 | ||
| The effectiveness and cost-effectiveness of biomarkers for the prioritisation of patients awaiting coronary revascularisation: a systematic review and decision model | Q37698695 | ||
| Cost-effectiveness of cerebrospinal biomarkers for the diagnosis of Alzheimer's disease | Q37708297 | ||
| Genetics of IL28B and HCV--response to infection and treatment | Q38013941 | ||
| Pharmacogenomics of adverse drug reactions: implementing personalized medicine | Q38036150 | ||
| Reducing safety-related drug attrition: the use of in vitro pharmacological profiling. | Q38063789 | ||
| Statistical spectroscopic tools for biomarker discovery and systems medicine | Q38101356 | ||
| Cancer systems biology in the genome sequencing era: part 1, dissecting and modeling of tumor clones and their networks. | Q38116255 | ||
| Cancer systems biology in the genome sequencing era: part 2, evolutionary dynamics of tumor clonal networks and drug resistance. | Q38116292 | ||
| The challenge of intratumour heterogeneity in precision medicine | Q38198785 | ||
| Lipidomics applications for disease biomarker discovery in mammal models | Q38358769 | ||
| Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization | Q38418590 | ||
| Biomarker: Predictive or Prognostic? | Q38590718 | ||
| Proteomic profiling of the cancer cell secretome: informing clinical research. | Q38659528 | ||
| Integrated precision medicine: the role of electronic health records in delivering personalized treatment | Q38756680 | ||
| Association of human leukocyte antigen variants and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: A meta-analysis | Q38822089 | ||
| SynLethDB: synthetic lethality database toward discovery of selective and sensitive anticancer drug targets | Q38823713 | ||
| Mutational Landscape and Sensitivity to Immune Checkpoint Blockers | Q38889870 | ||
| Predictive biomarkers of response to PD-1/PD-L1 immune checkpoint inhibitors in non-small cell lung cancer | Q38938285 | ||
| Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update | Q38961083 | ||
| Towards Precision Medicine in the Clinic: From Biomarker Discovery to Novel Therapeutics | Q39015855 | ||
| Biomarkers of response to PD-1/PD-L1 inhibition. | Q39426306 | ||
| HLA-B*57:01 Confers Susceptibility to Pazopanib-Associated Liver Injury in Patients with Cancer | Q40346340 | ||
| 5 year mortality predictors in 498,103 UK Biobank participants: a prospective population-based study | Q40863323 | ||
| Paying for personalized care: cancer biomarkers and comparative effectiveness | Q41376969 | ||
| A braided cancer river connects tumor heterogeneity and precision medicine | Q41522111 | ||
| Disease Biomarkers for Precision Medicine: Challenges and Future Opportunities | Q42355660 | ||
| Aldehyde dehydrogenase 2 gene is a risk factor for myocardial infarction in Japanese men. | Q44229504 | ||
| Drug-induced rhabdomyolysis: from systems pharmacology analysis to biochemical flux. | Q44268901 | ||
| Ethnic-specific obesity cutoffs for diabetes risk: cross-sectional study of 490,288 UK biobank participants | Q44330574 | ||
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 1535370217744775 | |
| P577 | publication date | 2017-01-01 | |
| P1433 | published in | Experimental Biology and Medicine | Q15716535 |
| P1476 | title | Biomarkers: Delivering on the expectation of molecularly driven, quantitative health |
| Q93243749 | A scientist engineer's contribution to therapeutic discovery and development | cites work | P2860 |
Search more.